Solventum, a healthcare company with a long legacy of innovation, announced that it has entered into a definitive agreement to acquire Acera Surgical for 725 million USD in cash, along with up to 125 million USD in additional contingent payments tied to future milestones. Acera, founded in 2013, develops fully engineered regenerative wound-care materials using its proprietary electrospinning technology. Its Restrata products are available across the USA and are used to treat complex, hard-to-heal wounds in acute care settings.

The acquisition strengthens Solventum’s advanced wound-care portfolio by combining Acera’s synthetic tissue matrix technologies with Solventum’s global commercial infrastructure, clinical relationships, and specialized wound-care sales force. This integration is expected to accelerate the adoption of Restrata products and generate commercial synergies.

“Regenerative wound care is a rapidly growing field, and Acera brings innovative technology that addresses a significant unmet need,” said Bryan Hanson, chief executive officer of Solventum. “This acquisition complements our existing portfolio and expands the solutions we can offer clinicians in acute care.”

Hanson noted that the move aligns with Solventum’s long-term transformation strategy, supported by strong financial performance. Acera is expected to generate approximately 90 million USD in revenue in 2025. Excluding the impact of potential share repurchases announced today, the transaction is projected to be slightly dilutive to adjusted earnings per share in 2026 and accretive beginning in 2027. Solventum plans to finance the acquisition entirely with cash on hand, without taking on additional debt.

The transaction is expected to close in the first half of 2026, subject to customary closing conditions. Morgan Stanley and Company LLC acted as financial advisor to Solventum, while Truist Securities advised Acera.